Compare Enveric Biosciences Inc (ENVB) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs TransMedics Group Inc — how do they compare? Enveric Biosciences Inc trades at $1.37 (market cap $5.32M), while TransMedics Group Inc trades at $75.81 (market cap $2.61B). The key difference: TransMedics Group Inc is far larger — about 490.6× Enveric Biosciences Inc's market cap, and TransMedics Group Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | TMDX | |
|---|---|---|
Market Cap | $5.32M | $2.61B |
Sector | Health | Technology |
52-Week High | $17.40 | $150.42 |
52-Week Low | $1.28 | $61.99 |
Enterprise Value | $408.82K | $3.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
TransMedics (TMDX) trades at $76.89, up 3.08% today, with a bullish technical signal from moving averages. The company reported strong profitability with a 27.04% net income margin and 45.22% ROE, though Q1 2026 earnings missed expectations. Recent strategic investment in PAD Aviation aims to expand its organ transplant logistics network in Europe, enhancing its competitive position.
The outlook remains positive with a consensus price target of $108.71, representing 41% upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion investments and competitive threats. Investors should weigh strong long-term growth initiatives against near-term execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
